JPWO2020227475A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227475A5 JPWO2020227475A5 JP2021566149A JP2021566149A JPWO2020227475A5 JP WO2020227475 A5 JPWO2020227475 A5 JP WO2020227475A5 JP 2021566149 A JP2021566149 A JP 2021566149A JP 2021566149 A JP2021566149 A JP 2021566149A JP WO2020227475 A5 JPWO2020227475 A5 JP WO2020227475A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- item
- domain
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020891A JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845306P | 2019-05-08 | 2019-05-08 | |
| US62/845,306 | 2019-05-08 | ||
| PCT/US2020/031781 WO2020227475A1 (en) | 2019-05-08 | 2020-05-07 | Cll-1 targeted immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Division JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532556A JP2022532556A (ja) | 2022-07-15 |
| JPWO2020227475A5 true JPWO2020227475A5 (https=) | 2023-05-15 |
| JP2022532556A5 JP2022532556A5 (https=) | 2023-05-15 |
Family
ID=73051177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566149A Pending JP2022532556A (ja) | 2019-05-08 | 2020-05-07 | Ｃｌｌ－１標的免疫療法 |
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020891A Pending JP2025081414A (ja) | 2019-05-08 | 2025-02-12 | Ｃｌｌ－１標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12421315B2 (https=) |
| EP (1) | EP3966249A4 (https=) |
| JP (2) | JP2022532556A (https=) |
| KR (1) | KR20220031549A (https=) |
| CN (1) | CN114502586B (https=) |
| AU (1) | AU2020267639A1 (https=) |
| BR (1) | BR112021022365A2 (https=) |
| CA (1) | CA3148027A1 (https=) |
| IL (1) | IL287769A (https=) |
| MA (1) | MA55905A (https=) |
| MX (1) | MX2021013590A (https=) |
| SG (1) | SG11202111927QA (https=) |
| WO (1) | WO2020227475A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20220004751A (ko) * | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| US12421315B2 (en) | 2019-05-08 | 2025-09-23 | Regeneron Pharmaceuticals, Inc. | CLL-1 targeted immunotherapies |
| CN119546328A (zh) * | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| US20250382636A1 (en) | 2022-05-26 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
| CN115772222B (zh) * | 2022-12-16 | 2024-03-29 | 浙江康佰裕生物科技有限公司 | 抗cll1单域抗体及其应用 |
| KR102908421B1 (ko) | 2025-04-16 | 2026-01-12 | (주)주인정보시스템 | 인공지능 기반 빌딩 자동제어 시스템 및 그 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| CZ206195A3 (en) | 1993-02-12 | 1996-04-17 | Univ Leland Stanford Junior | Controlled transcription of target genes and other biological materials |
| US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| ES2229236T3 (es) | 1994-01-11 | 2005-04-16 | Dyax Corporation | Inhibidores de la plasmina humana derivados de los dominios de kunitz. |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| AU766513B2 (en) | 1998-02-13 | 2003-10-16 | Board Of Trustees Of The Leland Stanford Junior University | Novel dimerizing agents, their production and use |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2010062966A2 (en) | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| EP2964253A1 (en) | 2013-03-05 | 2016-01-13 | Baylor College Of Medicine | Heparanase expression in human t lymphocytes |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| EP3288974B1 (en) | 2015-05-01 | 2020-11-04 | Inhibrx, Inc. | Type iii secretion system targeting molecules |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| EP3341410B1 (en) | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| WO2017180993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| AU2018385699B2 (en) | 2017-12-14 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Daric interleukin receptors |
| JP7060084B2 (ja) | 2018-03-26 | 2022-04-26 | 三菱マテリアル株式会社 | 絶縁回路基板用接合体の製造方法および絶縁回路基板用接合体 |
| US12097219B2 (en) | 2018-09-10 | 2024-09-24 | Legend Biotech Ireland Limited | Single-domain antibodies against CLL1 and constructs thereof |
| CA3121478A1 (en) | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| AU2019397152A1 (en) | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US20240034768A1 (en) | 2018-12-14 | 2024-02-01 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US12291560B2 (en) | 2018-12-14 | 2025-05-06 | Regeneron Pharmaceuticals, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| CA3139512A1 (en) | 2019-05-08 | 2020-11-12 | Inhibrx, Inc. | Cd123 targeted immunotherapies |
| US12421315B2 (en) | 2019-05-08 | 2025-09-23 | Regeneron Pharmaceuticals, Inc. | CLL-1 targeted immunotherapies |
| AU2020359530A1 (en) | 2019-09-30 | 2022-05-19 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2021207613A1 (en) | 2020-04-10 | 2021-10-14 | 2Seventy Bio, Inc. | Frb antibodies |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
-
2020
- 2020-05-07 US US17/608,738 patent/US12421315B2/en active Active
- 2020-05-07 CN CN202080049880.5A patent/CN114502586B/zh active Active
- 2020-05-07 KR KR1020217039632A patent/KR20220031549A/ko active Pending
- 2020-05-07 EP EP20801987.7A patent/EP3966249A4/en active Pending
- 2020-05-07 MA MA055905A patent/MA55905A/fr unknown
- 2020-05-07 CA CA3148027A patent/CA3148027A1/en active Pending
- 2020-05-07 JP JP2021566149A patent/JP2022532556A/ja active Pending
- 2020-05-07 WO PCT/US2020/031781 patent/WO2020227475A1/en not_active Ceased
- 2020-05-07 MX MX2021013590A patent/MX2021013590A/es unknown
- 2020-05-07 BR BR112021022365A patent/BR112021022365A2/pt unknown
- 2020-05-07 AU AU2020267639A patent/AU2020267639A1/en active Pending
- 2020-05-07 SG SG11202111927QA patent/SG11202111927QA/en unknown
-
2021
- 2021-11-01 IL IL287769A patent/IL287769A/en unknown
-
2025
- 2025-02-12 JP JP2025020891A patent/JP2025081414A/ja active Pending
- 2025-08-27 US US19/311,186 patent/US20260055192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113784732B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP2019518425A5 (https=) | ||
| AU2014259675B2 (en) | CS1-specific chimeric antigen receptor engineered immune effector cells | |
| CN109694854B (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| JP2023548844A (ja) | Ｃｄ７を標的にするキメラ抗原受容体及びその使用 | |
| US20230265154A1 (en) | Universal chimeric antigen receptor t-cell preparation technique | |
| US11286306B2 (en) | TLR9-binding chimeric antigen receptors | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| RU2020122708A (ru) | Рецепторы nkg2d daric | |
| Pircher et al. | T cell engineering | |
| JP2018526028A5 (https=) | ||
| BR112020000118A2 (pt) | receptores de antígenos quiméricos com domínios coestimulatórios cd28 mutados | |
| JP2021527409A5 (https=) | ||
| US20230272039A1 (en) | Gated adapter targeting receptor | |
| CN108138148A (zh) | T细胞的激活和扩增 | |
| US20210024608A1 (en) | Nkg2d chimeric antigen receptors | |
| AU2020316429B2 (en) | Composition and method for adoptive immunotherapy | |
| JPWO2020227475A5 (https=) | ||
| WO2020227595A1 (en) | Clec4-targeted car-t-cells | |
| JPWO2020227474A5 (https=) | ||
| JPWO2020227483A5 (https=) | ||
| JP2023528630A (ja) | エプスタイン－バーウイルスを標的とするｔｃｒ－ｔ細胞療法 | |
| JPWO2019241685A5 (https=) | ||
| JPWO2023196997A5 (https=) |